T here has been a marked global trend of increasing numbers of thin (#1.00 mm) melanomas. [1] [2] [3] [4] [5] With this shifting epidemiology, there is an increased need for identifying high-risk thin melanomas that will have worse outcomes. 6 Roughly 70% of all new melanomas are no more than 1.00 mm thick; however, these are still responsible for a quarter of melanoma deaths. 7 The American Joint Commission on Cancer (AJCC) has been developing staging guidelines since 1972 to help risk-stratify patients with cancer to guide treatments. The updated melanoma staging criteria are slated to go into effect in January 2018. 8, 9 Currently, high-risk features of thin melanomas include ulceration and a mitotic rate of 1 or higher. 8 The addition of mitotic rate to the staging criteria was met with several criticisms, and the 2018 update removes this variable for staging purposes. 9 Robust data found mitotic rate to be a predictor of overall survival and led to its inclusion in the staging criteria. [10] [11] [12] [13] [14] Others noted, however, that survival among patients with the thinnest melanomas (0.01-0.50 mm) with an elevated mitotic rate was still better than that among patients with thicker ones (0.51-1.00 mm) without an elevated mitotic rate. 8, 15 This study sought to evaluate the relationship between mitotic rate, ulceration, and positive sentinel nodes by using a large national database.
METHODS
This study was approved by the institutional review board of Vanderbilt University Medical Center and used the National Cancer Database (NCDB) melanoma file. The NCDB is a national registry that collects registry data from all Commission on Cancereaccredited facilities. It is reported to register more than 70% of all cancers occurring in the United States. 16 Data captured include clinical and pathologic tumor, node, and metastasis (TNM) staging; pathologic features such as Breslow depth, ulceration, and mitotic rate; and demographic information. A mitotic rate entered as less than 1 was considered a rate of 0, as no numeric value could be obtained from the database, and per NCDB data collection, a mitotic rate of 11 or greater was coded as 11. The NCDB begins registering cases among individuals age 18 years and older, and those older than age 90 are coded as age 90.
In preliminary analyses of the data, there was considerable discrepancy between the clinical and pathologic staging entered. There were also 105,311 cases listed as Tx for both clinical and pathologic staging, whereas an additional 2375 cases were missing both of these variables. In discussion with the NCDB, this potentially arose from the data collection rubric stating that the first values for each listed in the chart are to be used. For example, if the first staging entered in the chart came after the initial skin biopsy but before excision or sentinel lymph node biopsy, the staging might be listed T1aNxMx. Upon excision, there potentially could be upstaging if the melanoma was found to invade more deeply, have ulceration, or have an elevated mitotic rate. The most common discrepancy was for those entered initially as TxNxMx and then listed as a T1. As the NCDB is not linked to patient records to allow clarification of staging, it was decided that the staging would be derived from Breslow depth, mitotic rate, and presence or absence of ulceration. The rationale for this was that all information should be available from the initial pathology report and would be unlikely to be missing. The clinical decision to undergo a sentinel lymph node biopsy (SLNB) is made upon receipt of the initial biopsy report as well.
Therefore it seemed most rational to use the data that would be available at this branch point for analyses that would guide the decision to undergo SLNB. Because analyses focused on mitotic rate, all cases were reclassified on the basis of the 2010 staging guidelines. Differences between groups were tested by using chi-square analysis, the Student t test, or analysis of variance for categoric or continuous variables, respectively, or the Mann-Whitney U or KruskalWallis test for non-normally distributed continuous variables. The Pearson correlation coefficient was used to measure the linear association between mitotic rate and lymph node positivity. Multiple logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Because T stage was derived from variables already in the model, an additional adjustment for this was not included in the models. A 2-sided P value less than .05 was considered statistically significant. All analyses were conducted with SAS software (version 9.1, SAS Institute Inc, Cary, NC) or R software (version 3.3.1, R Project for Statistical Computing, Vienna, Austria).
RESULTS
There were 419,787 patients with melanoma in the NCDB from 2004 to 2013. Of these, 171,366 had a recorded Breslow depth of 0.01 to 1.00 mm. We excluded 9497 patients who were missing ulceration data and an additional 12,596 who were missing mitotic rate after 2010. Recording of these data for cases before the updated guidelines was not mandated, so we did not excluded those cases before 2010 that were missing data on mitotic rate. The final sample size included 149,273 thin melanomas (Fig 1) . Of these, 122,347 were T1a, and 26,926 were T1b on the basis of the 2010 AJCC guidelines (Table I ). The mean patient age was 58.6, there were more males (54.1%) than females (45.9%), and the patients were predominantly white (97.4%). A total of 52,865 patients underwent SLNB,
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with detection of 5188 positive nodes (9.8%). There were data on mitotic rate available on 17,204 of these, with 1746 positive nodes (10.1%).
The mean mitotic rate increased with the number of lymph nodes sampled (Table II) . Those who were found to have a positive node had a statistically significantly greater mean mitotic rate of 3.46 plus or minus 3.55 compared with 1.54 plus or minus 2.07 for those who were found to have a negative SLNB result (Mann-Whitney U test, P \.0001) (Table II) .
There was a highly statistically significant association between rate of lymph node positivity and mitotic rate (R 2 = 0.96, P \.0001, b = 3.31) (Fig 2 and Table III ). When only those with either a clinical or pathologic T1 from the chart and a Breslow depth of 1.00 or less were examined, the trend remained highly significant, though not as steep (R 2 = 0.87, P \.0001, b = 2.06). In logistic models adjusting for age, sex, Breslow depth, ulceration, and race, cases with a mitotic rate of 1 or more were more than twice as likely to have a positive lymph node than those with a mitotic rate less than 1 (OR, 2.13; 95% CI, 1.92-2.37) (Table IV) . When mitotic rate was treated as a continuous variable, there was a 19% increase in odds of a positive node per mitosis (OR, 1.19; 95% CI, 1.17-1.21) (Table IV) . There were no significant differences in 30-or 90-day survival between those with an elevated mitotic rate who did or did not There were 6696 cases with a mitotic rate of 1 or higher who did not undergo a SLNB. Of these, 9 were coded as having a nonzero N stage, and 32 had evidence of metastatic disease. The rest were coded as N0M0 (39.9%) or NxMx (60.0%).
Among the 121,077 cases excluded because of missing Breslow depth, there were 2505 cases listed as being T1, T1a, or T1b by either clinical or pathologic staging. Of these, 245 had data on mitotic rate, with the rate being 1 or higher in 66 cases. Data on nodal positivity were available for 52 of these, with 5 positive nodes, only 1 of which was in a case with an elevated mitotic rate. Among the 9497 cases excluded because of missing ulceration data, there were 228 with data for both mitotic rate and lymph node status. There were 25 cases with positive nodes: 2 of 48 cases among those without an elevated rate (4.2%) and 23 of 180 among those with mitotic rate of 1 or higher (12.8%) (P = .09).
DISCUSSION
In a national database containing nearly 150,000 thin melanomas, including 17,000 cases with SLNB and data on mitotic rate, the odds of having a positive sentinel lymph node were strongly correlated with mitotic rate. Of those with an elevated mitotic rate, patients undergoing SLNB with a mitotic rate of 1 had a positive node 7.9% of the time (ranging to 44.5% with positive nodes among those with a mitotic rate of 11 or higher). With use of the 2010 AJCC staging guidelines cutoff of a mitotic rate of 1 or higher, this would capture 82.8% of all of the positive nodes detected in this data set. Although those patients with a mitotic rate of 1 to 3 had a lower odds of a positive SLNB result, these cases represent a much more common event, and this group makes up the majority of cases ultimately found to have a positive SLNB finding. Offering a SLNB to those with a mitotic rate of 2 or higher, for example, would identify only 58.2% of those with a positive node, whereas a threshold of 3 or higher would identify only 43.2%. These results are powerful in that the initial pathology report on a thin melanoma subjected to biopsy to its base contains sufficient information to make a strong estimate regarding the risk of having a positive node. This is not the first study to observe that mitotic rate was associated with positive node. [17] [18] [19] [20] Most recently, Wat et al observed a significant association between mitotic rate and lymph node positivity among melanomas of intermediate thickness (1.01-2.00 mm) but not among thin melanomas. 18 The study included 1072 cases, with only 166 thin melanomas and 15 with a positive node. Ten percent of those with an elevated mitotic rate had a positive SLNB, compared with 3.6% of those without an elevated rate, however, suggesting that the study was underpowered to detect a significant difference in this subgroup. Another group observed a statistically significant association between mitotic rate and both lymph node status and survival among 1524 melanomas of intermediate thickness but did not examine thin melanomas. 21 Most notably, 1 singlecenter study of 1764 melanomas did observe a significant association between tumor mitotic rate and overall survival in unadjusted analyses. 22 Other studies have failed to observe statistically significant associations between mitotic rate and lymph node positivity among thin melanomas; however, these were likely underpowered, as the largest had only 484 cases.
14,23-25 Our study included more than 17,000 patients with thin melanoma who underwent a SLNB and had data on mitotic rate, finding a strong correlation between mitotic rate and lymph node positivity.
Several studies have examined the impact of the 2010 AJCC staging guidelines. One single-center study found that 29% of cases were changed between T1a and T1b; all of those with positive lymph nodes were listed as T1b in both staging schemes. 26 Another single-center study observed a nonsignificant decrease in thin melanomas with an elevated mitotic rate after adoption of the 2010 guidelines. 27 Thus, a criticism of the addition of mitotic rate to the staging criteria was that it did no better at identifying high-risk thin melanomas. Moreover, it was suggested that an elevated mitotic rate should not warrant a SLNB, as it was not significantly associated with survival in a systematic review. 15 Many of the studies cited in this review did, however, show a trend toward lower survival with an elevated mitotic rate. 8, 12, 28, 29 Most of these had a much lower sample size than the current study, and it is likely that they were simply underpowered to detect a statistical difference. Balch et al observed that mitotic rate was the second strongest predictor of survival after Breslow depth among 10,233 melanomas, however. 8 An additional criticism of the use of mitotic rate for staging purposes had been that there were no treatments that could prolong survival to be offered in this subgroup. 15 Since the publication of this criticism, however, the field of melanoma immunotherapy with checkpoint inhibitors has expanded greatly, and studies have now shown survival benefit among patients with nodal and not just distant metastases. 30 Moreover, a positive node should no longer mandate an immediate completion, sparing the associated risk of lymphedema, as for most patients no survival benefit has been shown from the dissection. 31 There are, however, some data showing that patients with metastases larger than 2 mm, extracapsular extension, and multiple positive nodes may benefit from completion lymphadenectomy. 32 The inverse association with positive nodes and Breslow depth was curious, as the overwhelming bulk of the literature shows a worse prognosis with increasing Breslow depth. To determine whether this inverse association existed in the thin melanomas only, we reran the analysis using all cases with available data in the NCDB with all Breslow depths included (n = 52,569). In this larger set, an increasing Breslow depth was associated with increased odds of having a positive node (OR, 1.02; 95% CI, 1.02-1.02, P\.0001), which is consistent with the findings of the AJCC. This finding suggests that the inverse association was only among thin melanomas. When the thin melanomas only were looked at more closely, there was a marked predominance of T1b melanomas thinner than 0.75 mm, which is in agreement with international trends of seeing thinner melanomas. [1] [2] [3] [4] [5] The inverse association with Breslow depth is thus potentially related to the changing epidemiology of melanoma overall rather than to a systemic error in the data. Alternatively, many thin melanomas may have been treated outside of Commission on Cancereapproved facilities, and only those with positive nodes may have been referred to these centers and therefore registered in the database.
This study had several limitations. Most notably, the NCDB is not linked to individual pathology reports or case records, so collecting follow-up data for survival analyses was not possible. As such, these results can suggest an association but cannot be used as predictors of prognosis. Next, there was a high degree of missing data. We excluded more than 12,000 cases occurring after 2010 that were missing data on mitotic rate. This group had age, sex, race, and Breslow depth distributions similar to those for the cases with mitotic rate included, and logistic models for positive lymph node status yielded values similar to those from the included cases, making it unlikely that these exclusions would have created a spurious association. We also excluded cases missing data on Breslow depth or ulceration. Low numbers with available data precluded conducting analyses on the group missing Breslow depth. Among those missing data on ulceration only, however, there was a nonsignificant 3-fold increase in the proportion with positive nodes among those cases with an elevated mitotic rate compared with among those with a mitotic rate less than 1, suggesting that these exclusions did not affect the overall conclusions.
Not all cases with positive nodes had high-risk features. There were 301 cases with a mitotic rate less than 1 and a positive node. Of these, only 33 had ulceration, and 5 occurred before 2010, with no data on mitotic rate collected. Of those 301 patients with a mitotic rate less than 1 and a positive node, 97 had clinical evidence of nodal or metastatic spread on the bases of clinical N or M stage being nonzero, 51 were missing clinical TNM staging, and the remaining 153 had no evidence of high-risk features recorded.
A recent study identified decimal errors in the Surveillance, Epidemiology, and End Results data that falsely suggested a higher mortality among thin melanomas. 33 Upon linking to the records, these errors were corrected and the spike in mortality disappeared. Although it is not possible to link to individual records to search for these sorts of errors, when we excluded cases with a T stage listed in the chart as anything but T1, we observed a very similar trend. It would be highly unlikely that cases had both a decimal error in their Breslow depth and a downstaging error in their data entry to such a systematic degree as to create the association observed.
The eighth edition of the AJCC melanoma staging guidelines are slated to go into effect January 1, 2018. These guidelines will no longer contain mitotic rate as a criteria on the basis of a number of smaller studies that have failed to identify a significant association between mitotic rate and survival. In this large study of nearly 150,000 thin melanomas with more than 17,000 cases with mitotic rate data, we observed a highly statistically significant association between mitotic rate and SLNB positivity rate. These results suggest that mitotic rate should continue to be reported. Additional studies are needed to confirm the association between mitotic rate and having a positive node.
